Granuloma Annulare
10
0
1
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
10.0%
1 terminated out of 10 trials
87.5%
+1.0% vs benchmark
10%
1 trials in Phase 3/4
14%
1 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (10)
Using Artificial Intelligence to Help Doctors Identify Different Skin Conditions and Improve Patient Care
Tyrosine Kinase 2 (TYK2) for GA and CS
Janus Kinase Inhibition in Granuloma Annulare
Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare
Granuloma Annulare Treated With Rifampin, Ofloxacin, and Minocycline Combination Therapy
Evaluation of 41 Cases of Pediatric Granuloma Annulare
Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare
Pain Outcomes Following Intralesional Corticosteroid Injections
UVA1 Light for Scleroderma and Similar Conditions
Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix